Prostate cancer
mCRPC: novel and emerging agents

Wannes (72 years old)

Wannes, 72 years old, was a professional woodworker and created beautiful pieces of furniture. Since his retirement he creates dog and cat houses for the local animal shelter. For his granddaughter, he made some very nice doll houses. He was diagnosed with high-risk PCa 9 years ago (pT3aN0, ISUP grade 4, postoperative PSA <0.1 ng/ml). The disease progressed to mCRPC 5 years ago (bone). He received enzalutamide as first-line and 6 cycles docetaxel as second-line therapy.

Follow-up today (1 year after stopping docetaxel):

  • No comorbidities
  • No relevant family history
  • ECOG PS: 1
  • Fairly well controlled pain (VAS score 3)
  • Rising PSA: 110 ng/ml
  • PSMA-PET/CT: progression in bone only (all lesions without clear PSMA expression)
  • Somatic (tumour) testing: no mutation identified

Which of the following treatment options would you choose for this patient?